8-K: Aquestive Therapeutics Announces Positive Topline Results for Anaphylm Pediatric Study, Completes NDA Submission

Aquestive Therapeutics reports positive results from its pediatric study of Anaphylm sublingual film and completes the NDA submission to the FDA, with potential NDA acceptance expected in Q2 2025.

Summary

• Aquestive Therapeutics announced positive topline results from its pediatric study for Anaphylm (epinephrine) sublingual film.
• The study included patients aged seven to seventeen and weighing greater than thirty kilograms with a history of allergic reactions.
• The company has completed the New Drug Application (NDA) submission for Anaphylm to the FDA.
• Aquestive expects to receive potential acceptance of the NDA from the FDA during the second quarter of 2025.
• The pediatric study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of Anaphylm.
• Thirty-two patients completed the study, and the PK results were consistent with previous adult studies.
• Anaphylm was shown to be safe and well-tolerated with no serious adverse events (SAEs) reported.
• Aquestive plans to launch Anaphylm in the first quarter of 2026, if approved by the FDA.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful pediatric study results and the completion of the NDA submission. The company's anticipation of FDA acceptance and planned launch contribute to the optimistic outlook.

Positives

• Positive topline results from the pediatric study validate Anaphylm's potential as a convenient treatment option for severe allergic reactions.
• The completion of the NDA submission to the FDA is a significant milestone.
• The consistent PK profile in pediatric patients supports the inclusion of this patient population in the potential approved label.
• Anaphylm was shown to be safe and well-tolerated in the pediatric study.
• The company is preparing for commercial readiness and plans to launch Anaphylm in Q1 2026, pending FDA approval.

Risks

• The FDA may not accept the NDA or may require additional clinical studies for approval of Anaphylm.
• The launch of Anaphylm is contingent on FDA approval, which is not guaranteed.
• There are risks associated with commercializing a new product, including technology, financial, market, and implementation risks.
• The company faces competition from existing and potential competing products, including generics.
• There is a risk of insufficient capital and cash resources to fund commercialization activities.

Future Outlook

Aquestive anticipates potential FDA acceptance of the Anaphylm NDA in Q2 2025 and plans to launch Anaphylm in Q1 2026, contingent on FDA approval.

Management Comments

• Daniel Barber, President and Chief Executive Officer of Aquestive, stated that they are extremely pleased with the positive results from the pediatric study, which further validate Anaphylm's potential as the first-ever sublingual film and convenient treatment option for all patients with severe allergic reactions, including anaphylaxis.
• He also noted that the results demonstrate that Anaphylm maintains its consistent PK profile in pediatric patients between the ages of seven and seventeen and weighing greater than thirty kilograms.

Industry Context

The announcement positions Aquestive Therapeutics to potentially disrupt the anaphylaxis treatment market with a novel sublingual film formulation, offering a needle-free alternative to traditional epinephrine auto-injectors like EpiPen and Auvi-Q. This could address patient preferences for more convenient and less invasive administration methods.

Comparison to Industry Standards

• The current standard of care for anaphylaxis primarily involves epinephrine auto-injectors, such as EpiPen (Mylan, now Viatris) and Auvi-Q (Kaleo).
• These devices deliver an intramuscular injection of epinephrine.
• Aquestive's Anaphylm aims to provide a needle-free alternative through a sublingual film, potentially offering faster absorption and easier administration, especially for children and those with needle phobias.
• Key competitors in the allergy treatment market include companies like Viatris, Kaleo, and Teva Pharmaceuticals, which offer epinephrine auto-injectors and other allergy medications.
• The success of Anaphylm will depend on its ability to demonstrate comparable or superior efficacy and safety compared to existing auto-injectors, as well as its ease of use and patient acceptance.

Stakeholder Impact

• Shareholders may react positively to the news of successful clinical trial results and NDA submission.
• Patients with severe allergies, including anaphylaxis, may benefit from a new, convenient treatment option if Anaphylm is approved.
• The company's employees may be impacted by the commercialization efforts and potential success of Anaphylm.

Next Steps

• Aquestive awaits potential acceptance of the NDA from the FDA during the second quarter of 2025.
• The company will continue to prepare for commercial readiness in anticipation of a potential launch in the first quarter of 2026, pending FDA approval.

Key Dates

Keywords

Anaphylm, Aquestive Therapeutics, Epinephrine Sublingual Film, NDA Submission, Pediatric Study, Anaphylaxis, Allergic Reactions, FDA Approval